Praxis Investment Management Inc. Sells 6,460 Shares of Moderna, Inc. $MRNA

Praxis Investment Management Inc. lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 38.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,250 shares of the company’s stock after selling 6,460 shares during the period. Praxis Investment Management Inc.’s holdings in Moderna were worth $283,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. S Bank Fund Management Ltd bought a new position in shares of Moderna during the 1st quarter valued at about $25,000. TD Private Client Wealth LLC lifted its holdings in shares of Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares in the last quarter. SVB Wealth LLC bought a new position in shares of Moderna during the 1st quarter valued at about $28,000. CX Institutional lifted its holdings in shares of Moderna by 1,129.8% during the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after purchasing an additional 949 shares in the last quarter. Finally, Costello Asset Management INC bought a new position in shares of Moderna during the 1st quarter valued at about $30,000. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRNA. Leerink Partners cut their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. Morgan Stanley lifted their target price on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Cowen initiated coverage on Moderna in a research report on Sunday, July 13th. They issued a “hold” rating on the stock. Citigroup initiated coverage on Moderna in a research report on Friday, August 1st. They issued a “neutral” rating and a $40.00 target price on the stock. Finally, Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $39.93.

Moderna Stock Down 4.2%

NASDAQ:MRNA opened at $26.01 on Friday. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of -3.45 and a beta of 2.01. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $57.69. The stock’s 50 day moving average price is $25.91 and its two-hundred day moving average price is $27.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s quarterly revenue was down 41.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.